Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Click here to view

Presentation

Selective Repression of C9ORF72 Repeat Expansion-Containing Sense and Antisense Transcripts for the Treatment of ALS

Download PDF